Navigation Links
Rotech Announces Confirmation of Plan of Reorganization
Date:8/29/2013

ORLANDO, Fla., Aug. 29, 2013 /PRNewswire/ -- Rotech Healthcare Inc. (OTCBB: ROHI.OB) announced today that the U.S. Bankruptcy Court has approved the Second Amended Joint Plan of Reorganization of Rotech Healthcare Inc., along with $358 million of exit financing commitments received from Wells Fargo and certain existing holders of the 10.5% Senior Second Lien Secured Notes.

The reorganization plan was confirmed at a court hearing in Delaware and was supported by the Statutory Committee of Unsecured Creditors. Creditors entitled to vote overwhelmingly voted in favor of the reorganization plan.

At the time that the Company filed its reorganization cases on April 8, 2013, the Company said that it would reorganize its businesses and emerge from Chapter 11 within 90 to 150 days. The Company said that it expects to close on its exit financing commitment and formally emerge from Chapter 11 next month.

"We said at the outset this would be a swift passage through the reorganization process and it has been," said Steven P. Alsene, Rotech's President and Chief Executive Officer. "We have successfully completed an important milestone in the financial restructuring that positions Rotech to operate successfully in today's very competitive environment.

"We appreciate the strong support the Company has received from its lenders, creditors, suppliers, customers and especially its employees. With a restructured balance sheet, new long-term financing and a seasoned management team, Rotech is well-positioned for future leadership in the industry."

Under the reorganization plan, the Company's existing common stock will be cancelled and substantially all of the new common stock of reorganized Rotech will be distributed to holders of the 10.5% Senior Second Lien Secured Notes.

Proskauer Rose, LLP serves as the Company's legal advisor, Barclays as financial advisor and AlixPartners as restructuring advisor.

Wachtell Lipton Rosen & Katz serves as legal advisor to each of the Consenting Noteholders holding Second Lien Secured Notes.

About Rotech Healthcare Inc.

Rotech Healthcare Inc. is one of the largest providers of home medical equipment and related products and services in the United States, with a comprehensive offering of respiratory therapy and durable home medical equipment and related services. The Company provides home medical equipment and related products and services principally to older patients with breathing disorders, such as chronic obstructive pulmonary diseases (COPD), which include chronic bronchitis, emphysema, obstructive sleep apnea and other cardiopulmonary disorders. The Company provides equipment and services in 49 states through approximately 420 operating locations located primarily in non-urban markets.

Forward-Looking Statement

Information set forth herein (including information included or incorporated by reference herein) contains "forward-looking statements" (as defined in Section 21E of the Exchange Act), which reflect the Company's expectations regarding future events. The forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those contained in the forward-looking statements. Such forward-looking statements include, but are not limited to that the Company will have sufficient cash on hand to pay its operating expenses; the Company's ability to continue to comply with other covenants under its notes or credit facility; potential decreases in Medicare Part B reimbursement rates; legislative or regulatory changes to Medicare or related programs; health care reform, including recently enacted legislation; adjustments in reimbursement rates set by the Centers for Medicare & Medicaid Services; the effects of the competitive bidding process under Medicare; the accreditation of the Company's operating locations and their compliance with government standards for coverage and payment; the ability of the Company to develop, secure approval of and consummate a prearranged plan of chapter 11 reorganization; the Company's ability to improve its operating structure, financial results and profitability following emergence from chapter 11; the potential adverse effects of the chapter 11 proceedings on the Company's liquidity, results of operations, brand or business prospects; the Company's ability to generate or raise cash and maintain a cash balance sufficient to fund continued investments, capital needs and service its debt; the Company's ability to maintain contracts that are critical to its operation; the Company's ability to obtain and maintain normal terms with customers, suppliers and service providers; and the Company's ability to retain key executives, managers and employees. Additional factors that may affect future results are contained in the Company's filings with the Securities and Exchange Commission (the "SEC"), which are available at the SEC's website at www.sec.gov. The Company disclaims any obligation to update and revise statements contained in these materials based on new information or otherwise.


'/>"/>
SOURCE Rotech Healthcare Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Great Lakes NeuroTechnologies Awarded Patent For Technology To Treat Parkinsons Disease With Brain Stimulation During Sleep
2. MicroTechnologies Announces Award of Medical Device Contract Manufacturing Line
3. Rotech Receives Approval of First Day Motions; Approvals Ensure Operations Continue Normally
4. The Market for Neurotechnology 2012-2018
5. Neurotech Reports Announces New Conference Dedicated to Consumer Applications of Neurotechnology
6. Upsher-Smith Announces Commercial Availability Of Morphine Sulfate ER Capsules
7. Neurocrine Biosciences Announces the Start of Second Phase III Study of Elagolix in Endometriosis
8. Eisai Inc. Announces Non-Exclusive Licensing Agreement with Generic Drug Manufacturer to Provide Generic Version of donepezil HCl 23 mg
9. InspireMD Announces Participation in Two Investor Conferences in September
10. Morgan & Morgan Announces the Investigation of Hi-Tech Pharmacal Co., Inc. HITK
11. Bernstein Liebhard LLP Announces That A Class Action Has Been Filed Against Biolase, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... , May 24, 2016 ... Education in Clinical Neurophysiology  Elsevier , ... products and services, today announced the launch of ... open access journal that focuses on clinical practice issues ... case reports, clinical series, normal values and didactic reviews. ...
(Date:5/23/2016)... According to a new ... Product (Wheelchair, Scooters, Medical Beds, Bathroom Safety, Mechanical, ... Wound), Accessories (Lifting, Transfer) & by End User ... MarketsandMarkets, the patient handling equipment market is expected ... a CAGR of 10.5% during the forecast period ...
(Date:5/23/2016)... York , May 23, 2016 ... report titled, " Exocrine Pancreatic Insufficiency Market - Global ... - 2023 ." According to the report, the exocrine ... CAGR of 8.3% from 2015 to 2023 to reach ... (EPI) is a condition characterized by the deficiency of ...
Breaking Medicine Technology:
(Date:5/26/2016)... , ... May 26, 2016 , ... May 2016 – ... so central to popular cosmetic improvement efforts. Record numbers of clients now ask about ... prominent or pouty, says Kally Papantoniou, MD, of Advanced Dermatology P.C. , ...
(Date:5/26/2016)... ... May 26, 2016 , ... In 1980, Bill Howe opened AM/PM Sewer and ... community. His vision to grow the company was built on a simple mission of ... level of training and customer service. Over 35 years later, Bill Howe remains one ...
(Date:5/26/2016)... ... May 26, 2016 , ... Women’s athletic ... host their second pop-up shop for three consecutive weekends. The pop-up shop is ... Santa Barbara community, a community full of women who appreciate the most premium ...
(Date:5/25/2016)... ... May 26, 2016 , ... The 12th session of the Silicon Valley BioTalks ... in Palo Alto, CA. This Bay Area biotech event will focus on “Setting Up ... from the pharmaceutical company Hallux, biopharma Apexigen, Contract Research Organization (CRO) Experien Group, and ...
(Date:5/25/2016)... ... , ... Furthering its position as the industry leader in drug education and ... (Drug Free Sport®) is excited to expand on details of its “Sport Exchange Summit, ... in Kansas City, MO, will gather sports industry professionals to examine, address and challenge ...
Breaking Medicine News(10 mins):